论文部分内容阅读
目的 :观察以替尼泊苷为主的化疗方案治疗中枢神经系统淋巴瘤的疗效。方法 :8例原发性 /继发性中枢神经系统 (CNS)非霍奇金淋巴瘤 (NHL)患者 ,给予 COP+VM- 2 6方案化疗 ,7例给予全颅放疗 ,4例在放、化疗前手术切除颅内病灶。结果 :4例原发性 CNS- NHL 患者中 3例手术切除后化疗 ,1例患者未手术 ,仅采用放疗和化疗 ,4例均获得了完全缓解 ,中位无病生存时间 2 3.5月 ,中位总体生存时间 2 9月 ;对系统性 NHL 期伴有颅内浸润的患者 ,该方案可以迅速缓解 CNS症状 ,3/ 4例 CR。结论 :以替尼泊苷为主的化疗方案对 CNS- NHL 疗效较好。CNS- NHL 的治疗应采用综合疗法 ,即手术 +化疗 +放疗。
Objective: To observe the efficacy of teniposide-based chemotherapy in the treatment of central nervous system lymphoma. METHODS: Eight patients with primary / secondary central nervous system (CNS) non-Hodgkin’s lymphoma (NHL) were given chemotherapy with COP + VM-2 6 regimen, seven patients received whole-cell radiotherapy, four received exacerbation, Surgical removal of intracranial lesions before chemotherapy. RESULTS: Of the 4 patients with primary CNS-NHL, 3 had undergone surgical resection and chemotherapy, 1 had no surgery and only received radiotherapy and chemotherapy. All 4 patients achieved complete remission. The median disease-free survival time was 23.5 months. The overall survival time was 29 months. In patients with systemic NHL with intracranial infiltration, the regimen could quickly relieve CNS symptoms and 3/4 of CR patients. Conclusions: Teniposide-based chemotherapy regimens have a better effect on CNS-NHL. The treatment of CNS-NHL should be used in combination therapy, surgery + chemotherapy + radiotherapy.